Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
about
Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.The future of multiple sclerosis treatments.TNFR1 inhibition with a Nanobody protects against EAE development in mice.
P2860
Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
@en
type
label
Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
@en
prefLabel
Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
@en
P2860
P1476
Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
@en
P2093
Radu Tanasescu
P2860
P304
P356
10.1517/17425255.2014.894019
P407
P577
2014-03-01T00:00:00Z